Granules India gets USFDA nod for generic drug used for short-term treatment of heartburn

Granules India gets USFDA nod for generic drug used for short-term treatment of heartburn

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

NSElive

• bselive
• nselive

Volume

Todays L/H

More

×

Granules India Ltd on Thursday said it has received approval from the US health regulator for its generic Esomeprazole Magnesium delayed-release capsules indicated for short-term treatment of heartburn and other symptoms associated with gastroesophageal reflux disease.

The approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Esomeprazole Magnesium delayed-release capsules of strengths 20 mg and 40 mg, Granules India said in a regulatory filing.

It is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Nexium Delayed-Release Capsules, 20 mg and 40 mg, of AstraZeneca Pharmaceuticals LP. Esomeprazole Magnesium capsules are indicated for short-term treatment of heartburn and other symptoms associated GERD, risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults and long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome, it added.

The current annual US market for Esomeprazole Magnesium delayed-release capsules is approximately USD 168 million, the company said citing IQVIA/IMS Health July 2023 data.